Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Beiderbeck, A. B.
Right arrow Articles by Leufkens, H. G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beiderbeck, A. B.
Right arrow Articles by Leufkens, H. G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Am J Epidemiol 2003; 157:510-516.
Copyright © 2003 by Johns Hopkins Bloomberg School of Public Health

ORIGINAL CONTRIBUTIONS

Prescription Medications Associated with a Decreased Risk of Non-Hodgkin’s Lymphoma

Annette B. Beiderbeck1,2, Elizabeth A. Holly3, Miriam C. J. M. Sturkenboom2, Jan W. W. Coebergh2, Bruno H. Ch. Stricker2 and Hubert G. M. Leufkens1,

1 Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, the Netherlands.
2 Pharmaco-epidemiology Unit, Departments of Epidemiology & Biostatistics and Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
3 Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA.

Earlier epidemiologic studies have suggested an inverse association between non-Hodgkin’s lymphoma and exposure to histamine2 (H2) blockers, nonsteroidal anti-inflammatory drugs, cholesterol-lowering drugs, and antibiotics. Data from the PHARMO database were used to conduct a nested, population-based case-control study that included 1985–1998 drug-dispensing records for 300,000 residents of six Dutch cities. Included were those subjects without a previous history of cancer who were aged >=20 years and were registered with an incident primary discharge diagnosis of non-Hodgkin’s lymphoma between 1991 and 1998. This paper includes data on 211 cases and 800 controls individually matched on sex, age, community pharmacy, calendar time, and duration of follow-up. Conditional logistic regression analysis was used to evaluate the association between non-Hodgkin’s lymphoma and categories of cumulative drug use in days. In multivariate analyses, nonsignificant risk reductions were found for all drugs tested, and the negative association tended to increase with increasing duration of use. For women, the odds ratio for H2 blockers was 0.29 (95% confidence interval: 0.12, 0.69) and for analgesics was 0.40 (95% confidence interval: 0.22, 0.71). Results support an inverse association between occurrence of non-Hodgkin’s lymphoma and use of H2 blockers and analgesics among women, and they warrant confirmation in larger studies.

antibiotics; anticholesteremic agents; anti-inflammatory agents, non-steroidal; histamine agents; lymphoma, non-Hodgkin; pharmacoepidemiology

Abbreviations: Abbreviations: H2, histamine2; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NSAID, nonsteroidal anti-inflammatory drug.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Bernatsky, J. L. Lee, and E. Rahme
Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories
Rheumatology, April 1, 2007; 46(4): 690 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. E. Smedby, E. Baecklund, and J. Askling
Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2069 - 2077.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. D. Flick, K. A. Chan, P. M. Bracci, and E. A. Holly
Use of Nonsteroidal Antiinflammatory Drugs and Non-Hodgkin Lymphoma: A Population-based Case-Control Study
Am. J. Epidemiol., September 1, 2006; 164(5): 497 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Fortuny, S. de Sanjose, N. Becker, M. Maynadie, P. L. Cocco, A. Staines, L. Foretova, M. Vornanen, P. Brennan, A. Nieters, et al.
Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH.
Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 921 - 925.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. T. Chang, K. E. Smedby, H. Hjalgrim, C. Schollkopf, A. Porwit-MacDonald, C. Sundstrom, E. Tani, F. d'Amore, M. Melbye, H.-O. Adami, et al.
Medication Use and Risk of Non-Hodgkin's Lymphoma
Am. J. Epidemiol., November 15, 2005; 162(10): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. R. Skibola, M. T. Smith, P. M. Bracci, A. E. Hubbard, L. Agana, S. Chi, and E. A. Holly
Polymorphisms in Ghrelin and Neuropeptide Y Genes Are Associated with Non-Hodgkin Lymphoma
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1251 - 1256.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.